Neuropsychiatric Symptoms of Alzheimer Disease, Parkinson Disease and Lewy Body Dementia: Genetic, Clinical and Therapeutic Overlaps
Leonardo Massoni. Advances in Geriatric Medicine and Research, 2025-07-07
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Apolipoprotein E-4 (APOE-4), serotonin transporter gene (SLC6A4), and single nucleotide polymorphisms (SNPs) of glucocerebrosidase (GBA) are some of the main altered genes in AD, PDD and DLB. From a molecular point of view, α-synuclein and β/τ-amyloid are the main-altered proteins whose alteration has been implicated in neuropsychiatric symptoms of the diseases, while the entorhinal and parahippocampal regions, medial temporal lobes, limbic regions, and brain stem are the main impaired cerebral regions. Electrophysiological studies provided some insights into the prevalence of neuropsychiatric alterations, including visual hallucinations and poorer cognitive performance, especially in DLB, and pointed out an hypometabolism in frontal, parietal, and temporal lobes in AD. Overall, AD, PD, and DLB may share clinical, neurochemical, and morphological characteristics, thus leading some authors to conceive a Lewy body disease spectrum. Further studies are warranted to find out clinical and neuropathological elements helping differential diagnosis between AD, PD dementia (PDD) and DLB.
What this study adds
Evidence grade: Low
This review describes shared genetic, molecular, and brain-region features among Alzheimer disease, Parkinson disease dementia, and Lewy body dementia, including APOE-4, SLC6A4, and GBA. The authors state further studies are warranted to help differential diagnosis, and no treatment, cure, or prevention is reported.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Massoni, L. (2025). Neuropsychiatric Symptoms of Alzheimer Disease, Parkinson Disease and Lewy Body Dementia: Genetic, Clinical and Therapeutic Overlaps. Advances in Geriatric Medicine and Research. https://doi.org/10.20900/agmr20250013
Vancouver
Massoni L. Neuropsychiatric Symptoms of Alzheimer Disease, Parkinson Disease and Lewy Body Dementia: Genetic, Clinical and Therapeutic Overlaps. Advances in Geriatric Medicine and Research. 2025. doi:10.20900/agmr20250013.
BibTeX
@article{massoni2025-371f2186,
author = {Massoni, Leonardo},
title = {{Neuropsychiatric Symptoms of Alzheimer Disease, Parkinson Disease and Lewy Body Dementia: Genetic, Clinical and Therapeutic Overlaps}},
journal = {Advances in Geriatric Medicine and Research},
year = {2025},
doi = {10.20900/agmr20250013},
url = {https://doi.org/10.20900/agmr20250013}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Apolipoprotein E-4 (APOE-4), serotonin transporter gene (SLC6A4), and single nucleotide polymorphisms (SNPs) of glucocerebrosidase (GBA) are some of the main altered genes in AD, PDD and DLB.
- From a molecular point of view, α-synuclein and β/τ-amyloid are the main-altered proteins whose alteration has been implicated in neuropsychiatric symptoms of the diseases, while the entorhinal and parahippocampal regions, medial temporal lobes, limbic regions, and brain stem are the main impaired cerebral regions.
- Electrophysiological studies provided some insights into the prevalence of neuropsychiatric alterations, including visual hallucinations and poorer cognitive performance, especially in DLB, and pointed out an hypometabolism in frontal, parietal, and temporal lobes in AD.
- Overall, AD, PD, and DLB may share clinical, neurochemical, and morphological characteristics, thus leading some authors to conceive a Lewy body disease spectrum.
- Further studies are warranted to find out clinical and neuropathological elements helping differential diagnosis between AD, PD dementia (PDD) and DLB.
Why it matters
This review describes shared genetic, molecular, and brain-region features among Alzheimer disease, Parkinson disease dementia, and Lewy body dementia, including APOE-4, SLC6A4, and GBA. The authors state further studies are warranted to help differential diagnosis, and no treatment, cure, or prevention is reported.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 27 of the 96 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Advances in Geriatric Medicine and Research) |
| Journal's citation record | 0 / 4 | Advances in Geriatric Medicine and Research: journal h-index 13 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Azienda USL Toscana Nord Ovest: institution h-index 77 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 27 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 96 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.20900/agmr20250013
- Original source →
- Free full text: Advances in Geriatric Medicine and Research →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Genetics from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.